MatriSys Bioscience

Industry
Biopharmaceuticals
Founded Year
2015
Headquarters
505 Coast Blvd S Ste 311, La Jolla, California, 92037, United States
Employee Count
14

Key People

Assessment

Team
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful track records in the MedTech industry.

The leadership includes individuals like Philippe Calais, who has over 35 years of experience in drug development, and Magda Marquet, a serial entrepreneur with multiple successful ventures in life sciences. Their combined expertise enhances the company's strategic direction and operational execution.

Clinical Need
Aspect: Very Strong
Summary: The company addresses significant unmet needs in dermatology, focusing on chronic skin diseases affecting millions worldwide.

MatriSys Bioscience is developing therapies for conditions such as atopic dermatitis, acne, and rosacea, which collectively affect over 230 million patients globally. The current treatment options often involve steroids and antibiotics, which have limitations and side effects. The company's approach using beneficial bacteria offers a novel and potentially safer alternative, addressing a critical gap in dermatological care.

Competition
Aspect: Somewhat crowded
Summary: The dermatology market is competitive, with several companies developing treatments for similar conditions.

The dermatology sector includes numerous players offering various treatments for skin conditions. However, MatriSys Bioscience's focus on harnessing beneficial bacteria to restore skin microbiome balance differentiates it from traditional therapies. This innovative approach could carve out a niche in a crowded market, provided it demonstrates superior efficacy and safety.

Technical Challenge
Aspect: Moderate
Summary: Developing live biotherapeutic products presents moderate technical challenges, including ensuring stability and efficacy.

The development of live biotherapeutic products involves challenges such as maintaining bacterial viability, ensuring consistent product formulation, and demonstrating clinical efficacy. MatriSys Bioscience's collaboration with experts like Dr. Richard Gallo and its robust research platform provide a solid foundation to address these challenges effectively.

Patent
Aspect: Very Strong
Summary: The company holds exclusive licenses and a broad patent position for its technology platform.

MatriSys Bioscience has secured exclusive licenses from the University of California San Diego and maintains a broad patent portfolio covering its technology platform. This strong intellectual property position protects its innovations and provides a competitive advantage in the market.

Financing
Aspect: Medium
Summary: The company has raised significant funding but may require additional capital to advance its pipeline.

MatriSys Bioscience has raised over $14 million across multiple funding rounds, including a $3 million bridge financing in 2021. However, advancing clinical programs through later-stage trials and commercialization will likely require additional capital. The company's ability to secure future funding will be crucial for its continued progress.

Regulatory
Aspect: Running FIH
Summary: The lead program is in Phase I/II clinical trials, indicating early-stage regulatory progress.

The company's lead program targeting atopic dermatitis is undergoing Phase I/II clinical trials. This early-stage progress is encouraging, but successful completion of later-stage trials and regulatory approvals are necessary before market entry. The company's strategic planning and execution in navigating the regulatory landscape will be critical to its success.

Opportunity Rollup

Odds of Success
4.15
Peak Market Share
5.45
Segment CAGR
5.4%
Market Segment
Dermatology
Market Sub Segment
Chronic Inflammatory Skin Diseases
Year Post Launch Market Penetration (%)
1 0.27
2 0.82
3 1.91
4 3.82
5 5.45

Key Takeaway

MatriSys Bioscience's innovative approach to treating chronic skin diseases using beneficial bacteria positions it well in a growing market, though it faces challenges in competition, financing, and regulatory approval.